SYDNEY, June 26, 2026, 07:02 (AEST)
- The ASX cash market sat in pre-open at the dateline, with normal trading set to begin at 09:59:45 Sydney time. June 26 isn’t included as a 2026 ASX closure.
- Sigma Healthcare finished the session at A$2.80 on June 25, gaining 2.56%.
- The stock’s gain for the day was in line with the S&P/ASX 200 Health Care index. The S&P/ASX 200 dropped 0.68%.
- Sigma’s most recent ASX statement is from June 15, when it said it was exiting the Boots sale.
Sigma Healthcare Ltd (ASX:SIG) opened Friday’s ASX session coming off a Thursday gain. The move was driven more by activity in health-care stocks than renewed interest in the Chemist Warehouse parent.
Sigma climbed 2.56% to A$2.80 on Thursday, matching the S&P/ASX 200 Health Care index (INDEXASX:XHJ), which also gained 2.56%. The broader S&P/ASX 200 (INDEXASX:XJO) slipped 0.68%. Sigma traded 25.74 million shares, about 48% higher than the 17.37 million share average shown by Google.
Sigma’s two-week chart tells the story. The stock ended at A$2.92 on June 9, then dropped after the Boots talks came out, bottoming at A$2.64 on June 12. Sigma closed at A$2.80 on June 15, after exiting the talks. On Thursday, shares finished 4.1% under June 9 and unchanged from June 15.
Stock price is still factoring in growth here. Sigma is at A$32.32 billion market cap as of Thursday, and trades at about 41 times its annualised first-half normalised profit. That’s based on A$392.0 million normalised NPAT for the six months ending Dec. 31. This is just a basic screen, not a full-year estimate. Company slides noted first-half results are typically ahead of the second half.
Sigma put out its half-year results. Revenue came in at A$5.5 billion. Normalised EBIT was A$582.9 million. Net debt stood at A$635.1 million, sitting at 0.6x normalised EBITDA. Sigma said it already booked A$13 million of early synergies out of a planned A$100 million a year by FY29.
The growth pitch is now tied more to stores and pharmacy sales than any major UK transaction. In a May update, Sigma said Chemist Warehouse sales in Australia jumped 16.7% year to April 30, with like-for-like up 14.4%. International store network sales grew 24.7% over the year to March 31, while like-for-like sales gained 11.8%. CEO Vikesh Ramsunder said GLP1-driven sales should be an “enduring benefit,” with the average GLP1 customer buying 40% more units per basket.
Boots remains an overhang for Sigma. Sigma on June 15 said it pulled out of early talks over the Boots Group sale. The board stopped discussions right away. Sigma said the deal didn’t fit its “strategic and capital investment objectives”. Still, the company said it will keep looking at deals in all markets.
No updated filings from the company, so Thursday’s move is still riding the wider health-care bounce. The investment case is unchanged. Local Chemist Warehouse and GLP1 sales are driving numbers. Offshore growth still needs to stay limited, or else old funding worries could come back like during the Boots episode.
Sigma’s smaller plan for the UK is still tied to GreenLight. In May, Sigma said it would pick up a 75% stake in some GreenLight Healthcare locations, license the Chemist Warehouse brand out, and start with as many as five stores for the first phase. Hoxton Street in northeast London is set as the location for the first store.
